CA2464578A1 — Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient

USPTO Abstract

The invention relates to a pharmaceutical formulation which is characterised by delayed release of the active ingredient. Said formulation contains 3-(3- dimethylamino-1-ethyl-2-methyl-propyl)phenol or one of its pharmaceutically acceptable salts in a matrix with delayed release of the active ingredient. Said matrix contains between 1 and 80 wt. % of at least one hydrophilic or hydrophobic polymer as a pharmaceutically acceptable matrix forming agent an d exhibits, in vitro, the following dissolution speed: between 3 and 35 wt. % (in relation to 100 wt. % of active ingredient) of 3-(3-dimethylamino-1-ethy l- 2-methyl-propyl)phenol is released after half an hour, between 5 and 50 wt. % of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol is released after one hour, between 10 and 75 wt. % of 3-(3-dimethylamino-1-ethyl-2-methyl- propyl)phenol is released after two hours, between 15 and 82 wt. % of 3-(3- dimethylamino-1-ethyl-2-methyl-propyl)phenol is released after three hours, between 30 and 97 wt. % of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol is released after six hours, more than 50 wt. % of 3-(3-dimethylamino-1-ethy l- 2-methyl-propyl)phenol is released after twelve hours, more than 70 wt. % of 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)phenol is released after eighteen hours, and morethan 80 wt. % of 3-(3-dimethylamino-1-ethyl-2-methyl- propyl)phenol is released after twenty-four hours.